In vitro inhibition of invasion and metastasis in colon cancer cells by TanIIA.

The purpose of this study was to investigate the effect of the traditional Chinese medicine TanIIA on the viability, invasion, and metastasis of SW480 cells. SW480 cells were treated with TanIIA for 24 h, and MTT assays were performed to determine the effect of TanIIA on cell viability. Transwell transmembrane experiments were applied to test the effect of 1.0 mg/mL TanIIA on SW480 cell invasion and metastasis abilities. Western blotting was performed to determine the expression of the tumor cell metastasis proteins E-cadherin, vimentin, and MMP-9. The cell growth inhibition rates were 0%, 26 ± 4.3%, 43.47 ± 4.0%, 63.0 ± 5.5%, and 76.8 ± 7.8% for treatment with 0, 0.5, 1.0, 2.0, and 5.0 mg/L TanIIA, respectively. The differences in the cell viability inhibitory rates among all groups were statistically significant (P < 0.05). The Transwell assay results indicated that SW620 cell invasion and metastasis abilities were strongly inhibited by 1.0 mg/mL TanII. The western blotting results showed that the expression of E-cadherin was significantly increased and that the expression levels of vimentin and MMP-9 were significantly decreased after treatment with 1.0 mg/mL TanII for 24 h (P < 0.05). Tan II can effectively inhibit the biological activity of colon cancer in vitro and prevent the invasion of colon cancer cells.

Analysis of tacrolimus blood concentrations in renal transplant patients.

This study aimed to 1) analyze the results of tacrolimus blood concentration monitored in patients after renal transplantation, 2) observe and establish an optimal therapeutic window for patients, and 3) provide evidence for the clinical and rational use of drugs. Tacrolimus blood concentration was determined by enzyme-linked immunosorbent assay. A total of 1824 cases were obtained from the monitoring of 74 patients after renal transplantation. These cases were then retrospectively analyzed. Over time, the mean whole blood tacrolimus trough concentration after transplantation gradually decreased. This result suggests that the optimal therapeutic windows for patients with renal transplants are as follows: 5 to 20 µg/L at 1 month after surgery; 5 to 15 µg/L at 1-3 months after surgery; 4 to 12 µg/L at 3-6 months after surgery; 4 to 10 µg/L at 6-12 months after surgery; and 3 to 8 µg/L at >12 months after surgery. The absorption of tacrolimus is highly variable. Therefore, tacrolimus concentration in the blood and the recommended clinical therapeutic window should be routinely monitored to adjust the treatment regimen and reduce adverse reactions. In this way, treatment can be optimized.